ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and Nasdaq (ticker symbol: PMN). ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
Pharmaceutical Preparation Manufacturing (325412)
Pharmaceutical and Medicine Industry (3741)
Stern Investor Relations
ProMIS Neurosciences, Inc.
1920 Yonge Street
Toronto, ON M4S 3E2